Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer

Sean T. Martin, Hiroyuki Matsubayashi, Carmelle D. Rogers, Juliet Philips, Fergus J Couch, Kieran Brune, Charles J. Yeo, Scott E. Kern, Ralph H. Hruban, Michael Goggins

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%) (odds ratio, 4.84; 95% CI, 1.27-18.55, P < 0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A > G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, P < 0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer - 7/250 (OR: 2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.

Original languageEnglish (US)
Pages (from-to)3652-3656
Number of pages5
JournalOncogene
Volume24
Issue number22
DOIs
StatePublished - May 19 2005

Fingerprint

Terminator Codon
Pancreatic Neoplasms
Adenocarcinoma
Nucleic Acid Heteroduplexes
Heteroduplex Analysis
Germ-Line Mutation
Cholecystectomy
Spouses
DNA Sequence Analysis
Epidemiologic Studies
Odds Ratio
Control Groups
Neoplasms

Keywords

  • BRCA2
  • Familial pancreatic cancer
  • K3326X

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Martin, S. T., Matsubayashi, H., Rogers, C. D., Philips, J., Couch, F. J., Brune, K., ... Goggins, M. (2005). Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene, 24(22), 3652-3656. https://doi.org/10.1038/sj.onc.1208411

Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. / Martin, Sean T.; Matsubayashi, Hiroyuki; Rogers, Carmelle D.; Philips, Juliet; Couch, Fergus J; Brune, Kieran; Yeo, Charles J.; Kern, Scott E.; Hruban, Ralph H.; Goggins, Michael.

In: Oncogene, Vol. 24, No. 22, 19.05.2005, p. 3652-3656.

Research output: Contribution to journalArticle

Martin, ST, Matsubayashi, H, Rogers, CD, Philips, J, Couch, FJ, Brune, K, Yeo, CJ, Kern, SE, Hruban, RH & Goggins, M 2005, 'Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer', Oncogene, vol. 24, no. 22, pp. 3652-3656. https://doi.org/10.1038/sj.onc.1208411
Martin, Sean T. ; Matsubayashi, Hiroyuki ; Rogers, Carmelle D. ; Philips, Juliet ; Couch, Fergus J ; Brune, Kieran ; Yeo, Charles J. ; Kern, Scott E. ; Hruban, Ralph H. ; Goggins, Michael. / Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. In: Oncogene. 2005 ; Vol. 24, No. 22. pp. 3652-3656.
@article{e2e3f38018bf4405bdf1642329a1414c,
title = "Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer",
abstract = "Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6{\%}) vs 3/250 controls (1.2{\%}) (odds ratio, 4.84; 95{\%} CI, 1.27-18.55, P < 0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A > G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, P < 0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer - 7/250 (OR: 2.37, 95{\%} CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.",
keywords = "BRCA2, Familial pancreatic cancer, K3326X",
author = "Martin, {Sean T.} and Hiroyuki Matsubayashi and Rogers, {Carmelle D.} and Juliet Philips and Couch, {Fergus J} and Kieran Brune and Yeo, {Charles J.} and Kern, {Scott E.} and Hruban, {Ralph H.} and Michael Goggins",
year = "2005",
month = "5",
day = "19",
doi = "10.1038/sj.onc.1208411",
language = "English (US)",
volume = "24",
pages = "3652--3656",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "22",

}

TY - JOUR

T1 - Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer

AU - Martin, Sean T.

AU - Matsubayashi, Hiroyuki

AU - Rogers, Carmelle D.

AU - Philips, Juliet

AU - Couch, Fergus J

AU - Brune, Kieran

AU - Yeo, Charles J.

AU - Kern, Scott E.

AU - Hruban, Ralph H.

AU - Goggins, Michael

PY - 2005/5/19

Y1 - 2005/5/19

N2 - Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%) (odds ratio, 4.84; 95% CI, 1.27-18.55, P < 0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A > G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, P < 0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer - 7/250 (OR: 2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.

AB - Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%) (odds ratio, 4.84; 95% CI, 1.27-18.55, P < 0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A > G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, P < 0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer - 7/250 (OR: 2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.

KW - BRCA2

KW - Familial pancreatic cancer

KW - K3326X

UR - http://www.scopus.com/inward/record.url?scp=19944414645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944414645&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1208411

DO - 10.1038/sj.onc.1208411

M3 - Article

C2 - 15806175

AN - SCOPUS:19944414645

VL - 24

SP - 3652

EP - 3656

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 22

ER -